Chemoproteomics-Based Design of Potent LRRK2-Selective Lead Compounds That Attenuate Parkinson’s Disease-Related Toxicity in Human Neurons
- 3 August 2011
- journal article
- letter
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 6 (10), 1021-1028
- https://doi.org/10.1021/cb2002413
Abstract
Leucine-rich repeat kinase-2 (LRRK2) mutations are the most important cause of familial Parkinson’s disease, and non-selective inhibitors are protective in rodent disease models. Because of their poor potency and selectivity, the neuroprotective mechanism of these tool compounds has remained elusive so far, and it is still unknown whether selective LRRK2 inhibition can attenuate mutant LRRK2-dependent toxicity in human neurons. Here, we employ a chemoproteomics strategy to identify potent, selective, and metabolically stable LRRK2 inhibitors. We demonstrate that CZC-25146 prevents mutant LRRK2-induced injury of cultured rodent and human neurons with mid-nanomolar potency. These precise chemical probes further validate this emerging therapeutic strategy. They will enable more detailed studies of LRRK2-dependent signaling and pathogenesis and accelerate drug discovery.This publication has 29 references indexed in Scilit:
- Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2Nature Chemical Biology, 2011
- Characterization of pharmacologically active compounds that inhibit poliovirus and enterovirus 71 infectivityJournal of General Virology, 2008
- Developmental regulation of leucine-rich repeat kinase 1 and 2 expression in the brain and other rodent and human organs: Implications for Parkinson’s diseaseNeuroscience, 2008
- Inhibition of ATF‐3 expression by B‐Raf mediates the neuroprotective action of GW5074Journal of Neurochemistry, 2008
- Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitorsNature Biotechnology, 2007
- The Familial Parkinsonism Gene LRRK2 Regulates Neurite Process MorphologyNeuron, 2006
- Kinase activity of mutant LRRK2 mediates neuronal toxicityNature Neuroscience, 2006
- Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degenerationProceedings of the National Academy of Sciences, 2005
- Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activityProceedings of the National Academy of Sciences, 2005
- Paradoxical activation of Raf by a novel Raf inhibitorCell Chemical Biology, 1999